Last reviewed · How we verify
Dimaval (unithiol)
Dimaval (generic name: unithiol) is a drug. It is currently in unknown development.
Dimaval works by binding to and neutralizing heavy metal ions, preventing them from causing cellular damage.
Dimaval, also known as 2,3-dimercapto-1-propanesulfonic acid, is a chelating agent that forms complexes with various heavy metals. It has been studied in clinical trials for the treatment of snakebite and Wilson's Disease.
At a glance
| Generic name | unithiol |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of Dimaval like a molecular 'glue' that sticks to heavy metal ions, preventing them from interacting with and harming cells. This helps to reduce the toxic effects of heavy metals in the body, allowing for their safe removal. By binding to these ions, Dimaval helps to restore balance and prevent further damage.
Approved indications
Common side effects
Key clinical trials
- Trial of Oral Community SVMP INhibitors for Snakebite (PHASE2)
- The Individual Therapy for Patients With Wilson's Disease (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dimaval CI brief — competitive landscape report
- Dimaval updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Dimaval
What is Dimaval?
How does Dimaval work?
What is the generic name of Dimaval?
What development phase is Dimaval in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing